Gower J D, Ambrose I J, Manek S, Bright J, Dobbin P S, Hider R C, Goddard J G, Thorniley M S, Green C J
Section of Surgical Research, MRC Clinical Research Centre, Harrow, Middlesex, UK.
Agents Actions. 1993 Sep;40(1-2):96-105. doi: 10.1007/BF01976757.
The effect of CP130 (a synthetic hexadentate pyridinone iron chelator) on the formation of two markers of lipid peroxidation (TBA-reactive material and Schiff's bases) in rabbit kidneys following a 72 h period of cold (0-4 degrees C) ischaemia was investigated by either adding CP130 to the flush/storage solution (hypertonic citrate solution) or by administering the agent intravenously 15 min before removal of the organs. In both cases, CP130 blocked the adverse rises in lipid peroxidation caused by ischaemia and subsequent reoxygenation of the homogenates in vitro. Both CP130 and desferrioxamine (DFX) (administered intravenously 15 min before ischaemia and 5 min before reperfusion) were also found to significantly reduce post-ischaemic rates of in vitro lipid peroxidation in kidneys rendered warm ischaemic for 90 min followed by reperfusion for 5 or 60 min in situ. Kidneys exposed to warm ischaemia and reperfusion developed interstitial and intracellular oedema, congestion and haemorrhage. DFX administration had little effect on the histological outcome, whereas CP130 significantly reduced interstitial oedema (at 5 min reperfusion compared to the DFX-treated group), intracellular oedema (at 60 min reperfusion compared to the DFX-treated group) and congestion (at 5 min reperfusion compared with a control group not given any agent). It is concluded that while CP130 and DFX exhibited similar antioxidant properties, CP130 provided better protection from ischaemia/reperfusion injury at the histological level. Synthetic iron chelators may therefore be of benefit in clinical organ transplantation by protecting against tissue damage caused by prolonged ischaemia.
研究了CP130(一种合成的六齿吡啶酮铁螯合剂)对家兔肾脏在72小时低温(0-4摄氏度)缺血后脂质过氧化的两个标志物(TBA反应性物质和席夫碱)形成的影响,方法是将CP130添加到冲洗/保存溶液(高渗柠檬酸盐溶液)中,或在器官切除前15分钟静脉给药。在这两种情况下,CP130均能阻断缺血及随后体外匀浆再给氧所引起的脂质过氧化的不良升高。还发现,CP130和去铁胺(DFX)(在缺血前15分钟和再灌注前5分钟静脉给药)均能显著降低肾脏在90分钟温缺血后再原位灌注5或60分钟时的缺血后体外脂质过氧化率。经历温缺血和再灌注的肾脏出现间质和细胞内水肿、充血和出血。给予DFX对组织学结果影响不大,而CP130显著减轻了间质水肿(再灌注5分钟时与DFX治疗组相比)、细胞内水肿(再灌注60分钟时与DFX治疗组相比)和充血(再灌注5分钟时与未给予任何药物的对照组相比)。结论是,虽然CP130和DFX表现出相似的抗氧化特性,但CP130在组织学水平上对缺血/再灌注损伤提供了更好的保护。因此,合成铁螯合剂通过防止长时间缺血引起的组织损伤,可能对临床器官移植有益。